Henry Schein (HSIC) Receiving Favorable Media Coverage, Analysis Finds
Press coverage about Henry Schein (NASDAQ:HSIC) has trended positive on Tuesday, AlphaOne Sentiment Analysis reports. AlphaOne, a unit of Accern, ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Henry Schein earned a daily sentiment score of 0.30 on AlphaOne’s scale. AlphaOne also gave media stories about the company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the stock’s share price in the near term.
These are some of the news articles that may have impacted Alpha One Sentiment Analysis’s scoring:
- A Quick Look at Henry Schein Inc (HSIC) – Nelson Research (nlrnews.com)
- Henry Schein, Inc. (HSIC) Given Consensus Rating of “Hold” by Brokerages (americanbankingnews.com)
- Henry Schein, Inc. (HSIC) Upgraded to “Outperform” at Robert W. Baird (americanbankingnews.com)
- Henry Schein (HSIC) Earns Media Sentiment Score of 0.02 (americanbankingnews.com)
- Company Watch for Henry Schein Inc (HSIC) – Stock Rover (thestockrover.com)
HSIC has been the subject of several research analyst reports. Gabelli raised Henry Schein from a “hold” rating to a “buy” rating and set a $208.00 price objective for the company in a research report on Tuesday, January 10th. Evercore ISI lifted their price objective on Henry Schein from $160.00 to $178.00 and gave the stock a “hold” rating in a research report on Tuesday, February 21st. Craig Hallum initiated coverage on Henry Schein in a research report on Tuesday, April 11th. They issued a “hold” rating for the company. Deutsche Bank AG initiated coverage on Henry Schein in a research report on Wednesday, March 15th. They issued a “hold” rating and a $174.00 price objective for the company. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $165.00 price objective on shares of Henry Schein in a research report on Tuesday, February 28th. Ten investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Henry Schein currently has an average rating of “Hold” and an average target price of $180.84.
Shares of Henry Schein (NASDAQ:HSIC) traded down 0.69% during mid-day trading on Tuesday, hitting $167.70. The stock had a trading volume of 311,628 shares. The firm has a market capitalization of $13.28 billion, a price-to-earnings ratio of 27.09 and a beta of 1.02. Henry Schein has a 1-year low of $146.23 and a 1-year high of $183.00. The stock’s 50-day moving average is $170.63 and its 200 day moving average is $160.42.
Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 21st. The company reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.03. Henry Schein had a net margin of 4.40% and a return on equity of 18.15%. The company earned $3.12 billion during the quarter, compared to analyst estimates of $3.08 billion. During the same period in the previous year, the business earned $1.67 earnings per share. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. Equities research analysts predict that Henry Schein will post $7.25 EPS for the current fiscal year.
In other Henry Schein news, EVP Mark E. Mlotek sold 5,559 shares of the company’s stock in a transaction dated Friday, March 17th. The shares were sold at an average price of $170.98, for a total transaction of $950,477.82. Following the completion of the sale, the executive vice president now directly owns 40,426 shares in the company, valued at $6,912,037.48. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Paul Rose sold 6,821 shares of the company’s stock in a transaction dated Wednesday, February 22nd. The shares were sold at an average price of $173.24, for a total transaction of $1,181,670.04. Following the sale, the senior vice president now owns 24,674 shares of the company’s stock, valued at $4,274,523.76. The disclosure for this sale can be found here. Insiders sold 67,670 shares of company stock valued at $11,650,932 over the last quarter. 1.27% of the stock is owned by company insiders.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.